08/23/2012
Reported online last week in Science Translational Medicine, researchers at MIT and Harvard used nanoparticles to demonstrate the nanoparticles that target a protein called ID4 can reduce ovarian cancer tumors in mice.
Researchers hope that this approach could help speed the development of new drugs. As new technology allows researchers to sequence cancer cell genomes, researchers are finding more and more gene mutations and deletions that may be therapeutic targets. This approach—using a mouse model to determine which ones are important—may help researchers prioritize which ones to focus drug development efforts on.
Click here for the abstract.
Related Topics

OCRA’s Early Career Investigator Grant Recipients
Ovarian Cancer Research Alliance is proud to support five outstanding scientists through our Early Career Investigator Grants, part of the $6 million in new research OCRA is funding in 2025. These … Continued

OCRA’s Collaborative Research Development Grant & Microsoft AI for Health Grantees
OCRA is proud to announce the first three recipients of the $6 million we have awarded to support groundbreaking ovarian and related gynecologic cancer research in 2025. And we’re not … Continued

CDC Report Shows Drop in Cervical Precancer Among HPV Vaccinated Age Group
Rates of cervical precancer dropped nearly 80% between 2008 and 2022 among screened women aged 20 to 24, according to the latest Morbidity and Mortality Weekly Report from Centers for Disease … Continued